21 CFR Part 11 Audit Active
Ingest Protocol

Protocol Ingestion & Criteria Decomposition

Upload an oncology protocol or select a clinical template to extract machine-executable inclusion and exclusion rules.

1Select Protocol Source

Choose a verified oncology trial template or paste custom protocol text

Phase IIINCT04035486

Phase III Osimertinib + Chemotherapy in Advanced EGFR-Mutated NSCLC

A randomized, open-label, international multi-center Phase 3 study evaluating frontline third-generation EGFR-TKI in patients with EGFR exon 19 deletion or L858R mutation.

Phase IINCT03734029

Phase II Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer

A Phase 2 multicenter study of antibody-drug conjugate (T-DXd) in patients with pretreated HER2-low unresectable or metastatic breast adenocarcinoma.

Automatic Safe-Harbor 18-Identifier De-identification Active